KR101475189B1 - Ｃ형 간염 바이러스 억제제 - Google Patents

Ｃ형 간염 바이러스 억제제 Download PDF

Info

Publication number
KR101475189B1
KR101475189B1 KR1020147010437A KR20147010437A KR101475189B1 KR 101475189 B1 KR101475189 B1 KR 101475189B1 KR 1020147010437 A KR1020147010437 A KR 1020147010437A KR 20147010437 A KR20147010437 A KR 20147010437A KR 101475189 B1 KR101475189 B1 KR 101475189B1
Authority
KR
South Korea
Prior art keywords
mmol
tfa
methanol
water
vacuo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147010437A
Other languages
English (en)
Korean (ko)
Other versions
KR20140066768A (ko
Inventor
캐롤 버챈드
마코넨 벨레마
다니엘 에이치. 데온
앤드류 씨. 굿
제이슨 굿리치
클린트 에이. 제임스
리코 라보이
오마르 디. 로페즈
알라인 마르텔
니콜라스 에이. 민웰
반 엔. 구엔
제프리 리 로마인
에드워드 에이치. 루디거
로렌스 비. 스나이더
데니스 알. 세인트 로렌트
푸캉 양
데이비드 알. 랭글리
간 왕
로렌스 지. 하만
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38812845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101475189(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20140066768A publication Critical patent/KR20140066768A/ko
Application granted granted Critical
Publication of KR101475189B1 publication Critical patent/KR101475189B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147010437A 2006-08-11 2007-08-09 Ｃ형 간염 바이러스 억제제 Expired - Fee Related KR101475189B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83699606P 2006-08-11 2006-08-11
US60/836,996 2006-08-11
US11/835,462 2007-08-08
US11/835,462 US8329159B2 (en) 2006-08-11 2007-08-08 Hepatitis C virus inhibitors
PCT/US2007/075544 WO2008021927A2 (en) 2006-08-11 2007-08-09 Hepatitis c virus inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097004970A Division KR101450352B1 (ko) 2006-08-11 2007-08-09 Ｃ형 간염 바이러스 억제제

Publications (2)

Publication Number Publication Date
KR20140066768A KR20140066768A (ko) 2014-06-02
KR101475189B1 true KR101475189B1 (ko) 2014-12-22

Family

ID=38812845

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097004970A Expired - Fee Related KR101450352B1 (ko) 2006-08-11 2007-08-09 Ｃ형 간염 바이러스 억제제
KR1020147010437A Expired - Fee Related KR101475189B1 (ko) 2006-08-11 2007-08-09 Ｃ형 간염 바이러스 억제제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020097004970A Expired - Fee Related KR101450352B1 (ko) 2006-08-11 2007-08-09 Ｃ형 간염 바이러스 억제제

Country Status (31)

Country Link
US (7) US8329159B2 (OSRAM)
EP (5) EP2049522B1 (OSRAM)
JP (3) JP5235882B2 (OSRAM)
KR (2) KR101450352B1 (OSRAM)
CN (1) CN104447707B (OSRAM)
AR (1) AR063684A1 (OSRAM)
AU (1) AU2007286222B2 (OSRAM)
BR (1) BRPI0716483B8 (OSRAM)
CA (1) CA2660520C (OSRAM)
CL (1) CL2007002327A1 (OSRAM)
CO (1) CO6150171A2 (OSRAM)
CY (4) CY1115594T1 (OSRAM)
DK (3) DK3042901T3 (OSRAM)
EA (1) EA015756B1 (OSRAM)
ES (3) ES2662590T3 (OSRAM)
HR (3) HRP20140737T1 (OSRAM)
HU (2) HUE029145T2 (OSRAM)
IL (1) IL196813A (OSRAM)
LT (2) LT3042901T (OSRAM)
LU (1) LU92635I2 (OSRAM)
MX (1) MX2009001426A (OSRAM)
NL (1) NL300713I2 (OSRAM)
NO (2) NO340543B1 (OSRAM)
NZ (1) NZ574805A (OSRAM)
PE (1) PE20080542A1 (OSRAM)
PL (3) PL2049522T3 (OSRAM)
PT (2) PT3042901T (OSRAM)
SI (3) SI2049522T1 (OSRAM)
TW (1) TWI432426B (OSRAM)
WO (1) WO2008021927A2 (OSRAM)
ZA (1) ZA200900962B (OSRAM)

Families Citing this family (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100055071A1 (en) * 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
CL2008001234A1 (es) * 2007-04-30 2008-09-22 Genentech Inc Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
CN102872461A (zh) 2007-05-04 2013-01-16 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ITMI20071012A1 (it) * 2007-05-18 2008-11-19 St Microelectronics Srl Dispositivo di memoria migliorato a veloce programmazione
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
ES2551352T3 (es) * 2007-07-05 2015-11-18 Array Biopharma, Inc. Pirimido ciclopentanos útiles para el tratamiento de enfermedades inflamatorias o hiperproliferativas
US8629171B2 (en) * 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
NZ583970A (en) 2007-10-11 2011-04-29 Univ California Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase
WO2009102694A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Heterocyclic derivatives as hepatitis c virus inhibitors
NZ587323A (en) * 2008-02-12 2012-02-24 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2008350334B2 (en) * 2008-02-13 2013-10-17 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis C virus inhibitors
AU2009279924B2 (en) 2008-08-02 2014-10-02 Genentech, Inc. Inhibitors of IAP
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010042834A1 (en) * 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
JP2012510523A (ja) 2008-12-03 2012-05-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
HK1203929A1 (en) * 2008-12-03 2015-11-06 普雷西迪奥制药公司 Inhibitors of hcv ns5a
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
EP2393359A4 (en) * 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
CA2753313A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US10752611B2 (en) 2009-02-27 2020-08-25 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2755658A1 (en) * 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
CA2756255A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI476190B (zh) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
TW201038559A (en) * 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102459165B (zh) * 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
MX2011011136A (es) * 2009-04-24 2011-11-18 Tibotec Pharm Ltd Eteres diarilicos.
AU2010249080A1 (en) * 2009-05-12 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
AU2014203349B2 (en) * 2009-05-13 2014-11-27 Gilead Sciences, Inc. Antiviral compounds
AU2013202666B2 (en) * 2009-05-13 2015-07-16 Gilead Sciences, Inc. Antiviral compounds
HUE036906T2 (hu) * 2009-05-13 2018-08-28 Antivirális vegyületek
AU2010253790A1 (en) * 2009-05-29 2011-12-15 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AU2012203474B2 (en) * 2009-06-11 2014-09-18 Abbvie Ireland Unlimited Company Anti-Viral Compounds
CA2737601C (en) * 2009-06-11 2014-10-21 Abbott Laboratories Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
IN2012DN00999A (OSRAM) 2009-07-16 2015-04-10 Vertex Pharma
WO2011015657A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
EP2462135A1 (en) 2009-08-07 2012-06-13 Janssen R&D Ireland Bis-benzimidazole derivatives as hepatitis c virus inhibitors
RU2012112824A (ru) 2009-09-03 2013-10-10 Тиботек Фармасьютикалз Производные бис-бензимидазола
MX2012002759A (es) 2009-09-04 2012-04-30 Glaxosmithkline Llc Compuestos quimicos.
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
EP2475254A4 (en) * 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011066241A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20110137633A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
JP5753185B2 (ja) * 2009-12-04 2015-07-22 ナショナル ヘルス リサーチ インスティテューツ プロリン誘導体
US8653070B2 (en) * 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011075607A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
PH12012501216A1 (en) * 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
US8362068B2 (en) * 2009-12-18 2013-01-29 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
KR20120130173A (ko) * 2009-12-24 2012-11-29 버텍스 파마슈티칼스 인코포레이티드 플라비바이러스 감염을 치료 또는 예방하기 위한 유사체들
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102843909A (zh) 2010-01-25 2012-12-26 埃南塔制药公司 丙型肝炎病毒抑制剂
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP2013518062A (ja) * 2010-01-28 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
CN102858157A (zh) 2010-03-04 2013-01-02 埃南塔制药公司 作为hcv复制的抑制剂的组合药物活性剂
AR080676A1 (es) 2010-03-09 2012-05-02 Schering Corp Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) * 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011119870A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) * 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2575866A4 (en) * 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CA2803248A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
JP2013531011A (ja) 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
WO2012009394A2 (en) * 2010-07-16 2012-01-19 Bristol-Myers Squibb Company Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication
US8815849B2 (en) 2010-07-26 2014-08-26 Janssen R&D Ireland Hetero-bicyclic derivatives as HCV inhibitors
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
BR112013004520A2 (pt) * 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
BR112013008148A2 (pt) * 2010-09-24 2016-08-09 Bristol Myers Squibb Co "inibidores do vírus da hepatite c".
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
JP5909495B2 (ja) 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
RS54619B1 (sr) * 2010-10-13 2016-08-31 Abbvie Bahamas Ltd. Antivirusni derivat 1-fenil-2,5-dibenzimidazol-5-il-pirolidina
AU2014203655B2 (en) * 2010-10-13 2016-07-07 Abbvie Ireland Unlimited Company Anti-viral compounds
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
CN103269586B (zh) 2010-10-26 2015-07-15 普雷西迪奥制药公司 丙型肝炎病毒抑制剂
WO2012061552A1 (en) 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus
CA3095528C (en) * 2010-11-17 2023-07-18 Gilead Pharmasset Llc Antiviral compounds
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
RU2452735C1 (ru) * 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
WO2012083048A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
US20150031884A1 (en) * 2010-12-15 2015-01-29 Abbvie Inc. Anti-viral compounds
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US8835456B1 (en) 2011-03-18 2014-09-16 Achillion Pharmaceuticals, Inc. NS5A inhibitors useful for treating HCV
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012158861A2 (en) 2011-05-18 2012-11-22 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
SG194681A1 (en) 2011-05-27 2013-12-30 Achillion Pharmaceuticals Inc Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
US20120328565A1 (en) 2011-06-24 2012-12-27 Brinkman John A Antiviral compounds
TW201317223A (zh) 2011-07-26 2013-05-01 Vertex Pharma 噻吩化合物
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
EA201490254A1 (ru) * 2011-08-24 2014-07-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Комбинированное лечение гепатита с
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
SMT201800087T1 (it) 2011-09-16 2018-03-08 Gilead Pharmasset Llc Metodi per trattare hcv
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US9180193B2 (en) 2011-10-10 2015-11-10 Hoffmann-La Roche Inc. Antiviral compounds
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
EP2773634B1 (en) * 2011-11-03 2018-06-06 Theravance Biopharma R&D IP, LLC Rod-like hepatitis c virus inhibitors containing the fragement {2-[4-(biphenyl-4-yl)-1h-imidazo-2-yl]pyrrolidine-1-carbonlymethyl}amine
UA119437C2 (uk) 2011-11-16 2019-06-25 Гайлід Фармассет Елелсі Противірусні сполуки
EP2782567B1 (en) 2011-11-22 2017-03-22 The Regents of The University of California Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa)
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MX2014006745A (es) 2011-12-16 2014-10-15 Hoffmann La Roche Inhibidores de hcv ns5a.
LT2794628T (lt) 2011-12-20 2017-07-10 Riboscience Llc 4`-azido-3`-fluoro pakeistieji nukleozido dariniai kaip hcv replikacijos inhibitoriai
PE20141423A1 (es) 2011-12-20 2014-10-16 Hoffmann La Roche Derivados nucleosidos con sustitucion 2',4'-difluoro-2'-metilo como inhibidores de la replicacion del arn del vhc
BR112014016007A8 (pt) 2011-12-28 2017-07-04 Janssen R&D Ireland derivados de quinazolinona como inibidores de vhc
WO2013098313A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Hetero-bicyclic derivatives as hcv inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
IN2014MN01547A (OSRAM) 2012-02-10 2015-05-08 Lupin Ltd
BR112014015582A8 (pt) 2012-02-24 2017-07-04 Hoffmann La Roche compostos antivirais
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
EP2850072B1 (en) 2012-04-25 2016-08-31 Theravance Biopharma R&D IP, LLC Hepatitis c virus inhibitors
SI2850075T1 (sl) 2012-04-25 2017-06-30 Theravance Biopharma R&D Ip, Llc Piperazin-piperidinske spojine kot inhibitorji virusa hepatitisa C
US8883135B2 (en) 2012-05-03 2014-11-11 Theravance Biopharma R&D Ip, Llc Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
JP6196678B2 (ja) * 2012-10-24 2017-09-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CN105073726B (zh) 2013-01-23 2017-05-31 弗·哈夫曼-拉罗切有限公司 抗病毒三唑衍生物
EA029081B9 (ru) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Комбинированный состав двух противовирусных соединений
RU2507201C1 (ru) 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CA2900319A1 (en) 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag Antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2014144547A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
WO2014144836A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
EP2990406B1 (en) * 2013-04-26 2018-12-26 Seoul National University R&DB Foundation Benzidine derivative, method for preparing same, and pharmaceutical composition containing benzidine derivative for treating liver disease caused by hepatitis c virus
CA2912682C (en) 2013-05-16 2021-07-06 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives
MA38678A1 (fr) 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP6333372B2 (ja) * 2013-07-09 2018-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤の組み合わせ
JP2016525114A (ja) * 2013-07-17 2016-08-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ
EP3021845A1 (en) * 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
EP3080104A1 (en) 2013-12-11 2016-10-19 Bristol-Myers Squibb Company 4,4'-biphenyldiyl-bis-(1 h-imidazolyl) derivatives as hepatitis hcv inhibitors
WO2015089810A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
SG11201607920RA (en) 2014-04-04 2016-10-28 X Rx Inc Substituted spirocyclic inhibitors of autotaxin
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
EP3166852B1 (en) 2014-07-08 2018-03-28 GIMA S.p.A. Unit and method for filling containing elements of single-use capsules for extraction or infusion beverages.
WO2016075588A1 (en) * 2014-11-11 2016-05-19 Sun Pharmaceutical Industries Limited Stable amorphous daclatasvir dihydrochloride
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
CN105753944B (zh) * 2014-12-19 2019-10-01 正大天晴药业集团股份有限公司 达卡他韦及其衍生物的制备中间体
WO2016102979A1 (en) 2014-12-26 2016-06-30 Cipla Limited Polymorphic forms of methyl((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof
CN106188015B (zh) * 2015-05-06 2019-10-18 广东东阳光药业有限公司 一种制备达卡他韦的方法
WO2016178250A1 (en) 2015-05-07 2016-11-10 Mylan Laboratories Limited Process for the preparation of daclatasvir
CZ2015366A3 (cs) 2015-05-29 2016-12-07 Zentiva, K.S. Pevné formy Daclatasviru
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017076358A1 (zh) * 2015-11-06 2017-05-11 苏州晶云药物科技有限公司 咪唑基联苯基化合物盐的新晶型及其制备方法
GB2552919A (en) * 2015-11-18 2018-02-21 Azad Pharmaceutical Ingredients Ag Stable amorphous form of daclatasvir
CN106083829B (zh) * 2016-01-12 2019-01-22 深圳市塔吉瑞生物医药有限公司 一种丙型肝炎病毒抑制剂、药物组合物及其应用
WO2017172476A1 (en) * 2016-03-28 2017-10-05 The University Of Toledo Potent inhibitors of aspartate n-acetyl-transferase for the treatment of canavan disease
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20190256498A1 (en) 2016-07-08 2019-08-22 Lupin Limited Crystalline forms of daclatasvir dihydrochloride
WO2018015847A1 (en) * 2016-07-18 2018-01-25 Glenmark Pharmaceuticals Limited Process for preparation of daclatasvir and salts
CN108069941A (zh) * 2016-11-15 2018-05-25 广东东阳光药业有限公司 一种制备达卡他韦的方法
RU2650610C1 (ru) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
US10392370B2 (en) * 2017-03-13 2019-08-27 Optimus Drugs Pvt Ltd Process for the preparation of Daclatasvir dihydrochloride and its intermediates
JP2020512331A (ja) 2017-03-22 2020-04-23 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 抗ｃ型肝炎ウイルス感染のためのケイ素含有化合物
CN109305962B (zh) * 2017-07-28 2022-01-18 扬子江药业集团有限公司 一种盐酸达拉他韦的精制方法
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
CN113167802B (zh) 2018-12-04 2025-02-07 百时美施贵宝公司 通过多同位素体反应监测使用样品内校准曲线的分析方法
WO2020219808A1 (en) * 2019-04-25 2020-10-29 Beta Pharma, Inc. Dicarbamate inhibitors of ns5a for treatment of hepatitis c virus infections and related diseases
TN2023000216A1 (en) 2021-03-10 2025-04-03 Jnana Therapeutics Inc Small molecule inhibitors of mammalian slc6a19 function
AU2022277904B2 (en) 2021-05-21 2025-06-12 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection
KR20240012476A (ko) 2021-05-21 2024-01-29 길리애드 사이언시즈, 인코포레이티드 지카 바이러스 저해제로서의 펜타사이클릭 유도체
JP2025531154A (ja) * 2022-09-14 2025-09-19 ジュニャーナ セラピューティクス インコーポレイテッド 哺乳類ｓｌｃ６ａ１９機能のコレクターを用いるｐｋｕの処置
WO2025122482A1 (en) * 2023-12-04 2025-06-12 Henry Ford Health System Methods and compositions to inhibit tribbles 2 for cancer therapy
CN119707774A (zh) * 2024-12-24 2025-03-28 浙江工业大学 一种微波辅助1,5,6,7-四氢-4h-吲哚-4-酮衍生物的溴化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133326A1 (en) 2005-06-06 2006-12-14 Bristol-Myers Squibb Company Inhibitors of hcv replication

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
JPH08505854A (ja) 1993-01-14 1996-06-25 マガイニン ファーマシューティカルズ，インク． 修飾された末端を有するアミノ酸及びペプチド
JP2001505585A (ja) * 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
EP1322604A1 (de) * 2000-09-22 2003-07-02 Bayer CropScience AG Delta 1-pyrroline für den einsatz als pestizide
WO2004002940A1 (en) 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Inhibitors of hcv ns5b polymerase
AU2003249977A1 (en) 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
US7183302B2 (en) 2002-08-12 2007-02-27 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of HCV replication
DE10243939A1 (de) * 2002-09-24 2004-04-01 Bayer Cropscience Ag Pyrroline
US7220745B2 (en) * 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
GB0326168D0 (en) 2003-11-10 2003-12-17 Arrow Therapeutics Ltd Chemical compounds
US7514434B2 (en) * 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
AU2005238270A1 (en) 2004-04-28 2005-11-10 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
ES2325865T3 (es) * 2004-07-26 2009-09-22 Eli Lilly And Company Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos.
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
GB2438802A (en) 2005-02-28 2007-12-05 Univ Rockefeller Structure of the hepatitis C virus NS5A protein
HRP20100542T1 (hr) 2005-09-16 2010-11-30 Arrow Therapeutics Limited Derivati bifenila i njihova uporaba za liječenje hepatitisa c
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
KR20080083139A (ko) 2006-01-11 2008-09-16 애로우 쎄라퓨틱스 리미티드 항-바이러스제로 사용하기 위한트리아졸로아닐리노피리미딘 유도체
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
WO2007138242A1 (en) 2006-05-30 2007-12-06 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) * 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8629171B2 (en) * 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US8181098B2 (en) * 2008-06-11 2012-05-15 Freescale Semiconductor, Inc. Error correcting Viterbi decoder
TWI476190B (zh) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133326A1 (en) 2005-06-06 2006-12-14 Bristol-Myers Squibb Company Inhibitors of hcv replication

Also Published As

Publication number Publication date
BRPI0716483B8 (pt) 2021-05-25
EA200900298A1 (ru) 2009-10-30
DK2784075T3 (en) 2016-07-04
US8329159B2 (en) 2012-12-11
US9227961B2 (en) 2016-01-05
US10047056B2 (en) 2018-08-14
EP3042901B1 (en) 2018-01-24
NL300713I1 (OSRAM) 2015-12-29
PT2049522E (pt) 2014-08-29
HUE029145T2 (hu) 2017-02-28
TW200813029A (en) 2008-03-16
JP2015172064A (ja) 2015-10-01
JP5235882B2 (ja) 2013-07-10
SI3042901T1 (en) 2018-06-29
PL2784075T3 (pl) 2016-09-30
HRP20140737T1 (hr) 2014-09-12
US8642025B2 (en) 2014-02-04
EP2049522A2 (en) 2009-04-22
KR20140066768A (ko) 2014-06-02
BRPI0716483A2 (pt) 2016-06-07
ZA200900962B (en) 2010-02-24
WO2008021927A3 (en) 2008-05-29
PL2049522T3 (pl) 2014-10-31
JP2013151535A (ja) 2013-08-08
US20150011754A1 (en) 2015-01-08
MX2009001426A (es) 2009-02-17
NL300713I2 (OSRAM) 2015-12-29
US20170320833A1 (en) 2017-11-09
CY1119988T1 (el) 2018-12-12
EP2385048A1 (en) 2011-11-09
HK1201535A1 (en) 2015-09-04
EP2784075B1 (en) 2016-03-23
ES2476592T3 (es) 2014-07-15
WO2008021927A2 (en) 2008-02-21
IL196813A (en) 2013-04-30
AU2007286222B2 (en) 2012-06-28
NO340543B1 (no) 2017-05-08
US9758487B2 (en) 2017-09-12
PL3042901T3 (pl) 2018-07-31
CN104447707B (zh) 2017-04-12
NO2017036I1 (no) 2017-07-28
EP2784075A1 (en) 2014-10-01
IL196813A0 (en) 2009-11-18
NO20090447L (no) 2009-03-02
LTC2049522I2 (lt) 2016-12-27
CY2015004I1 (el) 2016-08-31
CA2660520A1 (en) 2008-02-21
DK3042901T3 (en) 2018-04-30
US9421192B2 (en) 2016-08-23
HRP20160410T8 (hr) 2019-04-19
KR101450352B1 (ko) 2014-10-15
KR20090040909A (ko) 2009-04-27
TWI432426B (zh) 2014-04-01
US8900566B2 (en) 2014-12-02
CN104447707A (zh) 2015-03-25
US20160067223A1 (en) 2016-03-10
HRP20160410T1 (hr) 2016-06-17
ES2573523T3 (es) 2016-06-08
US20140050695A1 (en) 2014-02-20
LT3042901T (lt) 2018-03-12
CL2007002327A1 (es) 2008-05-16
US20080050336A1 (en) 2008-02-28
JP5769749B2 (ja) 2015-08-26
EP3321263A3 (en) 2018-07-04
HK1126486A1 (en) 2009-09-04
US20160311778A1 (en) 2016-10-27
CY1115594T1 (el) 2016-08-31
BRPI0716483B1 (pt) 2018-10-09
EA015756B1 (ru) 2011-12-30
AR063684A1 (es) 2009-02-11
US20130034520A1 (en) 2013-02-07
DK2049522T3 (da) 2014-07-07
CO6150171A2 (es) 2010-04-20
HUE037802T2 (hu) 2018-09-28
PT3042901T (pt) 2018-03-19
SI2784075T1 (sl) 2016-05-31
EP3321263A2 (en) 2018-05-16
CY2015004I2 (el) 2016-08-31
LU92635I2 (fr) 2015-11-03
CA2660520C (en) 2015-01-13
EP3042901A1 (en) 2016-07-13
SI2049522T1 (sl) 2014-12-31
ES2662590T3 (es) 2018-04-09
HRP20180496T1 (hr) 2018-05-04
PE20080542A1 (es) 2008-05-16
EP2049522B1 (en) 2014-05-14
NZ574805A (en) 2011-09-30
AU2007286222A1 (en) 2008-02-21
JP2010500413A (ja) 2010-01-07
CY1117641T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
KR101475189B1 (ko) Ｃ형 간염 바이러스 억제제
KR101492672B1 (ko) Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
KR101468765B1 (ko) Ｃ형 간염 바이러스 억제제
KR101438851B1 (ko) Ｃ형 간염 바이러스 억제제
JP5232148B2 (ja) Ｃ型肝炎ウイルス阻害剤
US8846023B2 (en) Hepatitis C virus inhibitors
US7745636B2 (en) Hepatitis C virus inhibitors
CN101558059B (zh) 丙型肝炎病毒抑制剂
US20100158862A1 (en) Hepatitis C Virus Inhibitors
HK1126486B (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20171117

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

FPAY Annual fee payment

Payment date: 20181115

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20211216

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211216

St.27 status event code: N-4-6-H10-H13-oth-PC1903